Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

December 2023 | 168 pages | ID: A698267F4955EN
GMD Research

Abstracts

Asia Pacific pharmaceutical manufacturing industry market will grow by 11.3% annually with a total addressable market cap of $57.26 billion over 2023-2032. The growth is driven by the increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high R&D investment in pharmaceutical industry, increasing per capita healthcare expenditure, and technological advancements in manufacturing processes.

Highlighted with 90 tables and 69 figures, this 168-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry market in every aspect of the classification from perspectives of Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Based on Formulation, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration

By Consumer Group, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Children & Adolescents (17 years old and below)
• Adults (18-64 years old)
• Geriatric (65 years old and above)

By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications

By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs

By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• Retail Channels
• Non-retail Channels

By Manufacturing Facility, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2032 included in each section.

• In-house Facility
• Outsourced Facility

Geographically, the following national/local markets are fully investigated:

• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2032. The breakdown of national markets by Formulation, Route of Administration, and Drug Type over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Abbott Laboratories

Aenova Group

Amgen Inc.

AstraZeneca

Catalent Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences Inc.

GlaxoSmithKline plc

Johnson & Johnson

Lonza Group

Lupin Limited

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Patheon Inc.

Pfizer CentreSource

Sanofi SA

Takeda

(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
  2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY FORMULATION

3.1 Market Overview by Formulation
3.2 Tablets
3.3 Capsules
3.4 Injectable
3.5 Sprays
3.6 Suspensions
3.7 Powders
3.8 Other Formulations

4 SEGMENTATION OF ASIA PACIFIC MARKET BY ROUTE OF ADMINISTRATION

4.1 Market Overview by Route of Administration
4.2 Oral Medicine
4.3 Topical Medicine
4.4 Parenteral Medicine
4.5 Inhalations
4.6 Other Routes of Administration

5 SEGMENTATION OF ASIA PACIFIC MARKET BY CONSUMER GROUP

5.1 Market Overview by Consumer Group
5.2 Children & Adolescents (17 years old and below)
5.3 Adults (18-64 years old)
5.4 Geriatric (65 years old and above)

6 SEGMENTATION OF ASIA PACIFIC MARKET BY THERAPEUTIC APPLICATION

6.1 Market Overview by Therapeutic Application
6.2 Cardiovascular Diseases
6.3 Pain
6.4 Diabetes
6.5 Cancer
6.6 Respiratory Diseases
6.7 Neurological Diseases
6.8 Orthopedics
6.9 Other Applications

7 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG TYPE

7.1 Market Overview by Drug Type
7.2 Branded Prescription Drugs
7.3 Generic Prescription Drugs
7.4 OTC Drugs

8 SEGMENTATION OF ASIA PACIFIC MARKET BY DISTRIBUTION CHANNEL

8.1 Market Overview by Distribution Channel
8.2 Retail Channels
8.3 Non-retail Channels

9 SEGMENTATION OF ASIA PACIFIC MARKET BY MANUFACTURING FACILITY

9.1 Market Overview by Manufacturing Facility
9.2 In-house Facility
9.3 Outsourced Facility

10 ASIA-PACIFIC MARKET 2022-2032 BY COUNTRY

10.1 Overview of Asia-Pacific Market
10.2 Japan
10.3 China
10.4 Australia
10.5 India
10.6 South Korea
10.7 Rest of APAC Region

11 COMPETITIVE LANDSCAPE

11.1 Overview of Key Vendors
11.2 New Product Launch, Partnership, Investment, and M&A
11.3 Company Profiles
Abbott Laboratories
Aenova Group
Amgen Inc.
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences Inc.
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin Limited
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Patheon Inc.
Pfizer CentreSource
Sanofi SA
Takeda
RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032
Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change
Table 3. World Economic Outlook, 2021-2031
Table 4. World Economic Outlook, 2021-2023
Table 5. Scenarios for Economic Impact of Ukraine Crisis
Table 6. World Health Spending by Region, $ bn, 2013-2020
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry
Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, $ mn
Table 11. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, $ mn
Table 12. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 13. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, $ mn
Table 14. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, $ mn
Table 15. APAC Pharmaceutical Manufacturing Industry by Country, 2022-2032, $ mn
Table 16. Japan Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 17. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 18. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 19. China Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 20. China Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 21. China Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 22. Australia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 23. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 24. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 25. India Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 26. India Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 27. India Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 28. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, $ mn
Table 29. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, $ mn
Table 30. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, $ mn
Table 31. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2022-2032, $ mn
Table 32. Abbott Laboratories: Company Snapshot
Table 33. Abbott Laboratories: Business Segmentation
Table 34. Abbott Laboratories: Product Portfolio
Table 35. Aenova Group: Company Snapshot
Table 36. Aenova Group: Business Segmentation
Table 37. Aenova Group: Revenue by Product, 2018-2019, thousand Euro
Table 38. Aenova Group: Recent Developments
Table 39. Amgen Inc.: Company Snapshot
Table 40. Amgen Inc.: Approved Drugs or Therapeutic Biologicals
Table 41. Astrazeneca: Company Snapshot
Table 42. Catalent Inc.: Company Snapshot
Table 43. Catalent Inc.: Business Segmentation in 2018
Table 44. Catalent Inc.: Product Portfolio
Table 45. Catalent Inc.: Revenue, 2018-2020, $ million
Table 46. Catalent Inc.: Revenue by Region in 2018
Table 47. Eli Lilly and Company: Company Snapshot
Table 48. Eli Lilly and Company: Pharmaceutical Brands
Table 49. F. Hoffmann-La Roche: Company Snapshot
Table 50. F. Hoffmann-La Roche: Business Segmentation
Table 51. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn
Table 52. Gilead Sciences: Company Snapshot
Table 53. Gilead Sciences: Main Products
Table 54. GlaxoSmithKline: Company Snapshot
Table 55. GlaxoSmithKline: Business Segmentation
Table 56. GlaxoSmithKline: Product Portfolio
Table 57. GlaxoSmithKline: Revenue, 2018-2020, $ bn
Table 58. Johnson & Johnson: Company Snapshot
Table 59. Johnson & Johnson: Business Segments
Table 60. Lonza Group: Company Snapshot
Table 61. Lonza Group: Business Segmentation in 2018
Table 62. Lonza Group: Product Portfolio
Table 63. Lonza Group: Revenue by Region in 2018
Table 64. Lupin Limited: Company Snapshot
Table 65. Lupin Limited: Business Segmentation
Table 66. Merck & Co., Inc.: Company Snapshot
Table 67. Merck & Co., Inc.: Business Segmentation
Table 68. Merck & Co., Inc.: Revenue, 2018-2020, $ bn
Table 69. Novartis International AG: Company Snapshot
Table 70. Novartis International AG: Business Segmentation
Table 71. Novartis International AG: Revenue, 2017-2019, $ bn
Table 72. Novo Nordisk: Company Snapshot
Table 73. Novo Nordisk: Product Portfolio
Table 74. Patheon Inc.: Company Snapshot
Table 75. Patheon Inc.: Business Segmentation in 2018
Table 76. Patheon Inc.: Product Portfolio
Table 77. Patheon Inc.: Revenue, 2017-2019, $ billion
Table 78. Patheon Inc.: Revenue by Region in 2018
Table 79. Patheon Inc.: Recent Developments
Table 80. Pfizer CentreSource: Company Snapshot
Table 81. Pfizer CentreSource: Business Segmentation in 2018
Table 82. Pfizer CentreSource: Product Portfolio
Table 83. Pfizer CentreSource: Revenue, 2017-2019, $ billion
Table 84. Pfizer CentreSource: Revenue by Region in 2018
Table 85. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot
Table 86. Pfizer CentreSource: Recent Developments
Table 87. Sanofi: Company Snapshot
Table 88. Sanofi: Business Segmentation
Table 89. Sanofi: Revenue, 2018-2020, $ bn
Table 90. Takeda Pharmaceutical Co. Ltd.: Company Snapshot

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032
Figure 4. Asia Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn
Figure 5. World Healthcare Services Production, annual percentage change
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century
Figure 9. Leading Causes of Death in the World, 2000 and 2019, million
Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million
Figure 11. World Population 65 and Over, % of Total Population, 1950-2060
Figure 12. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 13. Investment Opportunity Analysis
Figure 14. Porter’s Fiver Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry
Figure 15. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue
Figure 16. Asia Pacific Addressable Market Cap in 2023-2032 by Formulation, Value ($ mn) and Share (%)
Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, $ mn
Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, $ mn
Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, $ mn
Figure 20. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, $ mn
Figure 21. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, $ mn
Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Powders, 2022-2032, $ mn
Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, $ mn
Figure 24. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue
Figure 25. Asia Pacific Addressable Market Cap in 2023-2032 by Route of Administration, Value ($ mn) and Share (%)
Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, $ mn
Figure 27. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, $ mn
Figure 28. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, $ mn
Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, $ mn
Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, $ mn
Figure 31. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue
Figure 32. Asia Pacific Addressable Market Cap in 2023-2032 by Consumer Group, Value ($ mn) and Share (%)
Figure 33. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, $ mn
Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, $ mn
Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, $ mn
Figure 36. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue
Figure 37. Asia Pacific Addressable Market Cap in 2023-2032 by Therapeutic Application, Value ($ mn) and Share (%)
Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, $ mn
Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, $ mn
Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, $ mn
Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, $ mn
Figure 42. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, $ mn
Figure 43. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, $ mn
Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, $ mn
Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, $ mn
Figure 46. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue
Figure 47. Asia Pacific Addressable Market Cap in 2023-2032 by Drug Type, Value ($ mn) and Share (%)
Figure 48. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, $ mn
Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, $ mn
Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, $ mn
Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue
Figure 52. Asia Pacific Addressable Market Cap in 2023-2032 by Distribution Channel, Value ($ mn) and Share (%)
Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, $ mn
Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, $ mn
Figure 55. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue
Figure 56. Asia Pacific Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value ($ mn) and Share (%)
Figure 57. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, $ mn
Figure 58. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, $ mn
Figure 59. Asia-Pacific Pharmaceutical Manufacturing Industry, 2022-2032, $ mn
Figure 60. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue
Figure 61. Contribution to APAC 2023-2032 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 62. Pharmaceutical Manufacturing Industry in Japan, 2022-2032, $ mn
Figure 63. Pharmaceutical Manufacturing Industry in China, 2022-2032, $ mn
Figure 64. Pharmaceutical Manufacturing Industry in Australia, 2022-2032, $ mn
Figure 65. Pharmaceutical Manufacturing Industry in India, 2022-2032, $ mn
Figure 66. Pharmaceutical Manufacturing Industry in South Korea, 2022-2032, $ mn
Figure 67. Pharmaceutical Manufacturing Industry in Rest of APAC, 2022-2032, $ mn
Figure 68. Growth Stage of Asia Pacific 3D Printing Industry over the Forecast Period
Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars)